메뉴 건너뛰기




Volumn 12, Issue 5, 2008, Pages 368-373

Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil

Author keywords

Chronic hepatitis B; Cost; Treatment

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE;

EID: 65449161437     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702008000500005     Document Type: Article
Times cited : (17)

References (21)
  • 1
    • 64949148074 scopus 로고    scopus 로고
    • Ministério da Saúde, Programa Nacional de Hepatites Virais, Brasília;
    • Ministério da Saúde - Programa Nacional de Hepatites Virais. Avaliação da Assistência às Hepatites Virais no Brasil. Brasília;2002:1-61.
    • (2002) Avaliação da Assistência às Hepatites Virais no Brasil , pp. 1-61
  • 2
    • 68349092468 scopus 로고    scopus 로고
    • Ministério da Saúde, Programa Nacional para a Prevenção e o Controle das Hepatites Virais. Disponível em:, 2007
    • Ministério da Saúde - Programa Nacional para a Prevenção e o Controle das Hepatites Virais. Disponível em: http://www.saude.gov.br/sps/areastecnicas/ hepatite.htm. 2007.
  • 3
  • 4
    • 33746339209 scopus 로고    scopus 로고
    • A treatment algorithm for management of chronic hepatitis b vírus infection in the United States: Na update
    • Keeffe E.B., Dieterich D.T., Han S.H., et al A treatment algorithm for management of chronic hepatitis b vírus infection in the United States: na update. Clin Gastroenterol Hepatol 2006;4:936-62.
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 936-962
    • Keeffe, E.B.1    Dieterich, D.T.2    Han, S.H.3
  • 5
    • 33644827226 scopus 로고    scopus 로고
    • Hoofnagle J.H. Hepatitis B - Preventable and now treatable. N Engl J Med 2006;354:1074-6.
    • Hoofnagle J.H. Hepatitis B - Preventable and now treatable. N Engl J Med 2006;354:1074-6.
  • 6
    • 33846107571 scopus 로고    scopus 로고
    • Cross-study analysis of relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients
    • Dienstag J.L., Lee-Jen Wei, Dong Xu, Bruce Kreter. Cross-study analysis of relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Invest 2007; 27:35-49.
    • (2007) Clin Drug Invest , vol.27 , pp. 35-49
    • Dienstag, J.L.1    Jen Wei, L.2    Xu, D.3    Kreter, B.4
  • 7
    • 33644818518 scopus 로고    scopus 로고
    • A comparison of entecavir and lamivudine for AgHBe-positive chronic hepatitis B
    • Chang T.T., et al. A comparison of entecavir and lamivudine for AgHBe-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
    • (2006) N Engl J Med , vol.354 , pp. 1001-1010
    • Chang, T.T.1
  • 8
    • 33644822860 scopus 로고    scopus 로고
    • Entecavir versus lamivudine for patients with HBenegative chronic hepatitis B
    • Lai C.L., et al. Entecavir versus lamivudine for patients with HBenegative chronic hepatitis B. N Engl J Med 2006;354:1011-20.
    • (2006) N Engl J Med , vol.354 , pp. 1011-1020
    • Lai, C.L.1
  • 9
    • 29944436855 scopus 로고    scopus 로고
    • Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    • Chen C.J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73;
    • (2006) JAMA , vol.295 , pp. 65-73
    • Chen, C.J.1
  • 10
    • 33644858331 scopus 로고    scopus 로고
    • Predicting cirrhosis risk base don the level of circulating hepatitis B viral load
    • Iloeje U.H., et al. Predicting cirrhosis risk base don the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-86.
    • (2006) Gastroenterology , vol.130 , pp. 678-686
    • Iloeje, U.H.1
  • 11
    • 33644818518 scopus 로고    scopus 로고
    • A comparison of entecavir and lamivudine for AgHBe-positive chronic hepatitis B
    • Chang T.T., Gish R.G., Man R., et al. A comparison of entecavir and lamivudine for AgHBe-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
    • (2006) N Engl J Med , vol.354 , pp. 1001-1010
    • Chang, T.T.1    Gish, R.G.2    Man, R.3
  • 12
    • 33644822860 scopus 로고    scopus 로고
    • Entecavir versus lamivudine for patients with AgHBe-negative chronic hepatitis B
    • Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with AgHBe-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20.
    • (2006) N Engl J Med , vol.354 , pp. 1011-1020
    • Lai, C.L.1    Shouval, D.2    Lok, A.S.3
  • 13
    • 38149096996 scopus 로고    scopus 로고
    • Estimativas de custo da hepatite B crônica no sistema único de saúde brasileiro em 2005.
    • Castelo A., Pessoa M.G., Barreto T.C.B.B. Estimativas de custo da hepatite B crônica no sistema único de saúde brasileiro em 2005. Rev Assoc Med Bras 2007;53:486-91.
    • (2007) Rev Assoc Med Bras , vol.53 , pp. 486-491
    • Castelo, A.1    Pessoa, M.G.2    Barreto, T.C.B.B.3
  • 14
    • 68349098324 scopus 로고    scopus 로고
    • Instituto Brasileiro de Geografia e Estatística IBGE, Disponível em:, 2008
    • Instituto Brasileiro de Geografia e Estatística (IBGE). Disponível em: www.ibge.gov.br. 2008.
  • 15
    • 0028137860 scopus 로고
    • DEALE-ing and discounting: A simple way to compute the accrued costs of preventive strategies
    • Durand-Zaleski I., Zaleski S. DEALE-ing and discounting: a simple way to compute the accrued costs of preventive strategies. Med Decis Making 1994;14:98-03.
    • (1994) Med Decis Making , vol.14 , pp. 98-03
    • Durand-Zaleski, I.1    Zaleski, S.2
  • 16
    • 0035128185 scopus 로고    scopus 로고
    • Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis
    • Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
    • (2001) Gut , vol.48 , pp. 251-259
    • Bolondi, L.1    Sofia, S.2    Siringo, S.3
  • 17
    • 0036840812 scopus 로고    scopus 로고
    • Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: A cohort study of 297 patients
    • Fattovich G., Pantalena M., Zagni I., et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002;97:2886-95.
    • (2002) Am J Gastroenterol , vol.97 , pp. 2886-2895
    • Fattovich, G.1    Pantalena, M.2    Zagni, I.3
  • 18
    • 68349107701 scopus 로고    scopus 로고
    • The impact of chronic hepatitis B on quality of life: A multinational study of utilities from infected and uninfected persons
    • December
    • Levy A.R., Kowdley K.V., Iloeje U., et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value in Health 2007 (December).
    • (2007) Value in Health
    • Levy, A.R.1    Kowdley, K.V.2    Iloeje, U.3
  • 19
    • 35549005997 scopus 로고    scopus 로고
    • Cost-effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B
    • Veenstra D.L., Sullivan S.D., Clarke L., et al. Cost-effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007; 25:963-77.
    • (2007) Pharmacoeconomics , vol.25 , pp. 963-977
    • Veenstra, D.L.1    Sullivan, S.D.2    Clarke, L.3
  • 20
    • 33748337737 scopus 로고    scopus 로고
    • Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis
    • Kanwal F., Farid M., Martin P., et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006;101:2076-89.
    • (2006) Am J Gastroenterol , vol.101 , pp. 2076-2089
    • Kanwal, F.1    Farid, M.2    Martin, P.3
  • 21
    • 40149083254 scopus 로고    scopus 로고
    • Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAgpositive chronic hepatitis B patients
    • Yuan Y., Iloeje U.H., Hay J., Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAgpositive chronic hepatitis B patients. J Manag Care Pharm 2008;14:21-33.
    • (2008) J Manag Care Pharm , vol.14 , pp. 21-33
    • Yuan, Y.1    Iloeje, U.H.2    Hay, J.3    Saab, S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.